Skip to main content

Table 5 De novo gene mutations in synchronous and metachronous lung metastasis in relation to treatment regimens

From: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

Case ID # syn/met Year of occurrence post PT Therapy regimen De novo mutations
1 met 5 Ardalan ABL1, FGFR3, KRAS, NRAS, RET, SMARCB1, STK11, TP53, VHL
3 met 2 FOLFOXIRI, FOLFOXIRI/Bevacizumab, Xeloda/Bevacizumab, CAPIRI, Mitomycin, FOLFOX AKT1, ALK, APC, ATM, CSF1R, EGFR, ERBB2, ERBB4, FBXW7, FGFR2, FGFR3, FLT3, GNA11, GNAQ, HNF1A, IDH1, JAK3, KDR, KIT, KRAS, MET, MLH1, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMO, SRC, STK11, TP53, VHL
4 met 2 FOLFOX, 5-FU/Mitomycin, FOLFIRI No de novo mutations
5 syn 2 3x FOLFOXIRI/Bevacizumab APC, ATM, FBXW7, FGFR3, KIT, KRAS, PIK3CA, PTEN, RB1, SMAD4, TP53, VHL
6 met 5 3x FOLFIRI/Bevacizumab, FOLFOX SMO
7 met 5 FOLFOX4 No de novo mutations
8 syn,met 1,2 FOLFOXIRI, FOLFOXIRI/Bevacizumab FBXW7
9 met 4,5,7 Xeloda STK11, VHL, SMO, FBXW7, ERBB4, GNA11, PDGFRA
10 met 6 RCTx No de novo mutations
11 met 2,4 FOLFIRI/Bevacizumab PTEN, FBXW7
12 met 2 RCTx, Xeloda, FOLFIRI/Bevacizumab, FOLFIRI APC
14 syn 1 2x FOLFOXIRI/Bevacizumab, FOLFIRI/Bevacizumab ABL1, AKT1, APC, ATM, BRAF, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FGFR3, FLT3, GNA11, GNAQ, IDH1, KIT, MET, PIK3CA, SMAD4, SMARCB1, TP53, VHL
  1. The table summarizes de novo mutations per case in relation to occurrence of metastasis and treatment regimens. RCTx radio/chemotherapy, Syn synchronous, met metachronous. Note that there is no direct correlation between specific treatment regimens and the number of de novo mutations and/or genes affected by de novo mutations. Refer to main text for details